Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Enalapril in Raynaud's phenomenon.

S D Janini1, D G Scott, J S Coppock

  • 1Department of Rheumatology, Medical School, University of Birmingham, U.K.

Journal of Clinical Pharmacy and Therapeutics
|April 1, 1988
PubMed
Summary

Enalapril reduced Raynaud

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Charles Dickens' favourite child and a new kind of ray.

Journal of clinical pharmacy and therapeutics·2016
Same author

Experimentally simulating high-rate behaviour: rate and temperature effects in polycarbonate and PMMA.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2014
Same author

Mechanics of particulate composites with glassy polymer binders in compression.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2014
Same author

Availability of methaqualone from commercial preparations: in vitro and in vivo studies in man.

British journal of clinical pharmacology·2012
Same author

An assessment of gastric emptying by breathalyser.

British journal of clinical pharmacology·2012
Same author

The influence of diphenhydramine on the absorption of methaqualone in man.

British journal of clinical pharmacology·2012

Area of Science:

  • Cardiovascular Pharmacology
  • Rheumatology
  • Clinical Trials

Background:

  • Raynaud's phenomenon involves episodic vasospasm of peripheral digits.
  • Primary Raynaud's and secondary Raynaud's (associated with scleroderma) present distinct clinical challenges.
  • Vasodilator therapy is a common approach to managing Raynaud's symptoms.

Purpose of the Study:

  • To evaluate the efficacy of enalapril in treating Raynaud's phenomenon.
  • To compare enalapril's effects against a placebo in a double-blind, cross-over design.
  • To assess enalapril's impact on both subjective and objective measures of Raynaud's attacks.

Main Methods:

  • Prospective, double-blind, cross-over trial involving 17 patients.
  • Patients received enalapril (20 mg daily) and placebo for 3 weeks each, separated by a 2-week washout.
  • Symptom frequency (diary) and cold challenge test (finger systolic pressure) were primary outcome measures.

Main Results:

  • Enalapril significantly reduced the frequency of Raynaud's attacks compared to placebo.
  • The reduction in attack frequency was more pronounced in patients with primary Raynaud's phenomenon.
  • No significant effect of enalapril was observed on the cold challenge test results.

Conclusions:

  • Enalapril demonstrates a therapeutic benefit in managing the symptoms of Raynaud's phenomenon.
  • The drug appears particularly effective for patients with idiopathic or primary Raynaud's.
  • Enalapril acts as a vasodilator, alleviating symptomatic episodes in Raynaud's patients.

Related Experiment Videos